Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...
Biotech company 10x Genomics (NASDAQ:TXG) reported in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s revenue to be around $612.5 million, close to ...
10X GENOMICS ($TXG) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.36 per share, beating estimates of -$0.48 by $0.12 ...
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on 10x Genomics (NASDAQ:TXG) in the last three months. The following table summarizes their recent ...
10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results